Breanna Keith, NP
Nurse Practitioner · Terre Haute, INNPI 1871070763
Payments from drug & device makers
Across 147 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$863
- Lilly USA, LLC$286
- Novo Nordisk$266
- AstraZeneca$247
- GSK$136
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$79
- plus $639 from 18 others
What the payments were for
- Food & beverage$2,516100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $863 |
| Lilly USA, LLC | 15 | $286 |
| Novo Nordisk | 13 | $266 |
| AstraZeneca | 14 | $247 |
| GSK | 9 | $136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $79 |
| Novartis | 3 | $71 |
| Pfizer | 4 | $67 |
| Dexcom, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Amgen | 3 | $48 |
| Boehringer Ingelheim | 2 | $47 |
| Mylan Specialty L.p. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Exact Sciences | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Biogen | 1 | $19 |
| Abbott | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,516 in reported general payments places this provider in the 85th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 54 | $64,021 |
| OzempicSemaglutide | 48 | $48,242 |
| EliquisApixaban | 36 | $35,564 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $34,424 |
| JardianceEmpagliflozin | 22 | $25,545 |
| RybelsusSemaglutide | 15 | $19,682 |
| VraylarCariprazine Hcl | 12 | $17,076 |
| MounjaroTirzepatide | 14 | $14,722 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $11,538 |
| Lamotrigine OdtLamotrigine | 27 | $10,614 |
| GemtesaVibegron | 11 | $7,417 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,412 |
| MyrbetriqMirabegron | 11 | $6,614 |
| Levothyroxine Sodium | 305 | $3,375 |
| Atorvastatin Calcium | 372 | $2,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $266 | $67,92463 claims |
| AstraZenecaFarxiga | $247 | $64,02154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $136 | $45,96268 claims |
| PfizerEliquis | $67 | $35,56436 claims |
| Boehringer IngelheimJardiance | $47 | $25,54522 claims |
| AbbVieVraylar, Namzaric | $863 | $24,48824 claims |
| Lilly USA, LLCMounjaro | $286 | $14,72214 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $6,61411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Terre Haute
- Lindsay GambleTerre Haute$13K
- Kindra ShepardTerre Haute$12K
- Lisa FergusonTerre Haute$11K
- Ashley McCammonTerre Haute$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.